ConductScience.org, home

Comparison · NCT03263091-b64ab026

DB Component: Roxadustat vs DB Component: Placebo: DB Component: Number of Participants Who Achieved TI ≥56 Consecutive Days Anytime During the Study

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. DB Component: Roxadustat vs DB Component: Placebo: DB Component: Number of Participants Who Achieved TI ≥56 Consecutive Days Anytime During the Study. Trial comparisons, record NCT03263091-b64ab026. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03263091-b64ab026

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.650.5410.745wilson
Risk in group 20.5090.3830.634wilson
Risk difference, group 1 minus group 20.141-0.02480.299newcombe hybrid score
Risk ratio, group 1 over group 21.280.9451.73log
Odds ratio, group 1 over group 21.790.8963.59log
Number needed to treat, for one more participant with the outcome on DB Component: Roxadustat than on DB Component: Placebo7.08from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1DB Component: RoxadustatParticipants received roxadustat 2.5 mg/kg TIW for 52 weeks.5280OG000
Group 2DB Component: PlaceboParticipants received placebo matched to roxadustat for 52 weeks.2957OG001

Outcome

Type
SECONDARY
Title
DB Component: Number of Participants Who Achieved TI ≥56 Consecutive Days Anytime During the Study
Description
RBC TI was defined as the absence of any IV RBC transfusion (packed cell or whole blood) during any consecutive 56 days anytime during the study (up to Week 56).
Time frame
Baseline up to Week 56
Population
FAS included all enrolled participants who received at least 1 dose of study medication, and at least 1 corresponding on-treatment Hb assessment.

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
NCT number
NCT03263091
Phases
PHASE3
Conditions
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Interventions
Roxadustat, Placebo
Lead sponsor
Kyntra Bio
Results first posted
2024-08-01

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03263091-b64ab026